Alcon Inc. — FY2023 Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2023. This is an annual report, not a standalone 2023 Q4 results filing; quarterly-only figures are not provided in the supplied text. Financial statements are prepared under IFRS as issued by the IASB and reported in U.S. dollars.
Business context
Alcon develops and sells eye-care products through two segments: Surgical and Vision Care. It reported $9.37 billion of third-party net sales, operates in 56 countries, and serves markets in more than 140 countries. The United States represented 46% of sales.
Key financial metrics
| Metric | FY2023 | FY2022 |
|---|---|---|
| Net sales to third parties | $9.370 billion | $8.654 billion |
| Gross profit | $5.247 billion | $4.748 billion |
| Operating income | $1.039 billion | $672 million |
| Operating margin | 11.1% | 7.8% |
| Net income | $974 million | $335 million |
| Diluted EPS | $1.96 | $0.68 |
| Core operating income (non-IFRS) | $1.849 billion | $1.571 billion |
| Core operating margin (non-IFRS) | 19.7% | 18.2% |
| Core diluted EPS (non-IFRS) | $2.74 | $2.24 |
| Operating cash flow | $1.388 billion | $1.217 billion |
| Capital expenditure | $658 million | $636 million |
| Free cash flow (non-IFRS) | $730 million | $581 million |
| Total financial debt at year-end | $4.739 billion | $4.648 billion |
| Net debt (non-IFRS) at year-end | $3.643 billion | $3.660 billion |
| Cash and cash equivalents at year-end | $1.094 billion | $980 million |
Gross margin was approximately 56.0% of third-party sales in 2023, versus 54.9% in 2022. The company’s $1.1 billion of liquidity includes cash and derivative financial instruments. Its $1.32 billion revolving credit facility was undrawn at year-end. Management reported an average debt maturity of 10.7 years, with 97% of financial debt at fixed interest rates.
Performance and changes versus FY2022
- Net sales rose 8% reported and 10% at constant currencies. Surgical sales increased 5% reported (8% constant currency); Vision Care rose 12% (14% constant currency). Vision Care growth included 4% from products acquired in 2022.
- Surgical growth came mainly from consumables and equipment/other; implantables declined 1% reported. Vision Care growth reflected contact lens launches and pricing, acquired ophthalmic products, and improved contact-lens-care supply availability.
- Operating income increased 55% reported. Management cited higher sales and manufacturing efficiencies, partly offset by inflation, higher R&D spending, acquisition-related amortization, product mix and currency effects.
- Net income benefited from stronger operating income, lower other financial expense and a tax benefit, partly offset by higher interest expense. Interest expense rose to $189 million from $134 million, with increased debt following the Aerie acquisition contributing.
- Operating cash flow and free cash flow increased, although working capital absorbed cash, including from higher inventories and receivables and lower trade payables. Investing cash outflow was $1.094 billion, down from $1.865 billion in 2022, when acquisitions were a major use of cash.
- R&D expense increased to $828 million from $702 million, including investment following Aerie. The multiyear transformation program was completed by year-end 2023.
Outlook, commentary, risks and unusual items
- Management estimates the markets it serves will grow at a mid-single-digit annual rate from 2023 to 2028. This is market context, not company-specific revenue guidance; the supplied filing text does not provide a clear numerical FY2024 financial outlook.
- Inflationary costs, including labor, utilities, components, freight, resins and plastics, were partly addressed through pricing and productivity actions. Management warned that gross margin could face pressure in coming quarters as higher-cost inventory is sold.
- A $263 million discrete tax benefit followed a long-term agreement with Swiss tax authorities concerning deductibility of a statutory expense. The filing estimates OECD Pillar Two rules will increase the effective tax rate by approximately 1%–2% from 2024.
- Other notable items included a $58 million benefit from releasing an acquisition-related contingent liability; $139 million of transformation costs and $48 million of integration-related expenses; and a $199 million payment in 2023 under a previously accrued J&J Surgical Vision intellectual-property settlement. Prior-year operating results included $90 million of legal settlement costs and $62 million of intangible-asset impairments.
- Key exposures include foreign-exchange volatility, supply disruptions and reliance on limited-source suppliers, demand-forecasting and inventory risk, pricing and reimbursement pressure, regulatory approvals and product quality, competition and innovation execution, cybersecurity and data privacy, litigation, and the ability to service debt.
- Goodwill was $8.926 billion and the Alcon brand-name intangible asset was $2.980 billion at year-end; no impairment charges were recorded in 2023. The auditor identified impairment assessments for goodwill, the brand name and in-process R&D as critical audit matters.
- The company reported effective disclosure controls and internal control over financial reporting. PwC issued unqualified audit opinions on the IFRS financial statements and internal control over financial reporting.
Most important facts for investors to verify
- Reconcile reported and core results, particularly the $263 million Swiss tax benefit and the non-IFRS adjustments underlying core earnings and free cash flow.
- Assess whether margin expansion can persist as inflationary costs, currency movements and higher-cost inventory affect results.
- Monitor cash conversion, working capital, planned capital spending and debt service; review the terms and credit exposure of the $150 million Lifecore financing commitment.
- Evaluate goodwill, brand and acquired-intangible carrying values against the assumptions used in impairment testing, and track the Aerie and ophthalmic pharmaceutical pipeline.
- Track regulatory, reimbursement, patent-litigation and supplier risks, as well as execution of product launches and market-share gains in both segments.